Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
Journal of the American College of Cardiology|May 7, 2025
SGLT2 Inhibitors in Heart Failure: Iron Mobilization at the Heart of the MatterKieran F Docherty
JACC. Heart Failure|September 22, 2023
SGLT2 Inhibitors and Iron: More Than Meets the EyeKieran F Docherty
European Journal of Heart Failure|January 22, 2021
OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failureKieran F Docherty, Muthiah Vaduganathan
Trends in Cardiovascular Medicine|May 18, 2025
The role of finerenone in heart failureHassan Ismahel, Kieran F Docherty
JACC. Heart Failure|October 9, 2024
Reply: Beyond Remodeling: Interleukin-1 Blockade as a Therapeutic Strategy to Prevent Heart Failure After Myocardial InfarctionJaclyn Carberry, Kieran F Docherty
European Heart Journal. Quality of Care & Clinical Outcomes|December 18, 2021
Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?Kirsty McDowell, Kieran F Docherty
European Heart Journal|May 10, 2023
Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?Ross T Campbell, Kieran F Docherty
Heart (British Cardiac Society)|June 15, 2021
Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failureKieran F Docherty, Mark C Petrie
Heart (British Cardiac Society)|May 16, 2018
Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?Kieran F Docherty, Pardeep S Jhund
European Heart Journal|December 14, 2022
A welcome 'failure' of gliflozins: blood pressure reduction in heart failureKieran F Docherty, Pardeep S Jhund
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
Journal of the American College of Cardiology|May 7, 2025
SGLT2 Inhibitors in Heart Failure: Iron Mobilization at the Heart of the MatterKieran F Docherty
JACC. Heart Failure|September 22, 2023
SGLT2 Inhibitors and Iron: More Than Meets the EyeKieran F Docherty
European Journal of Heart Failure|January 22, 2021
OUTSTEP-HF: re-evaluating the role of physical activity measures in drug and device development in heart failureKieran F Docherty, Muthiah Vaduganathan
Trends in Cardiovascular Medicine|May 18, 2025
The role of finerenone in heart failureHassan Ismahel, Kieran F Docherty
JACC. Heart Failure|October 9, 2024
Reply: Beyond Remodeling: Interleukin-1 Blockade as a Therapeutic Strategy to Prevent Heart Failure After Myocardial InfarctionJaclyn Carberry, Kieran F Docherty
European Heart Journal. Quality of Care & Clinical Outcomes|December 18, 2021
Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure?Kirsty McDowell, Kieran F Docherty
European Heart Journal|May 10, 2023
Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance?Ross T Campbell, Kieran F Docherty
Heart (British Cardiac Society)|June 15, 2021
Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failureKieran F Docherty, Mark C Petrie
Heart (British Cardiac Society)|May 16, 2018
Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?Kieran F Docherty, Pardeep S Jhund
European Heart Journal|December 14, 2022
A welcome 'failure' of gliflozins: blood pressure reduction in heart failureKieran F Docherty, Pardeep S Jhund
Pageof 18